Clinical trial • Phase I • Other
EP102 for Advanced solid tumours
Phase I trial of EP102 for Advanced solid tumours. 92 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Advanced solid tumours
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 27-03-2025
- First CTIS Authorization Date
- 15-07-2025
Trial design
Phase I trial across 12 sites in France, Belgium, Czechia and others.
- Target Sample Size
- 92
Eligibility
Recruits 92 Vulnerable population not selected; no special consent or assent handling specified..
- Vulnerable Population
- Vulnerable population not selected; no special consent or assent handling specified.
Recruitment
- Planned Sample Size
- 92
- Recruitment Window Months
- 42
Geography
- Total Number Of Sites
- 12
- Total Number Of Participants
- 92
France
- Earliest CTIS Part Ii Submission Date
- 22-10-2025
- Latest Decision Or Authorization Date
- 29-10-2025
- Processing Time Days
- 7
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- Département d'innovation Thérapeutique et des Essais Précoces (DITEP)
- Principal Investigator Name
- Christophe Massard
- Principal Investigator Email
- christophe.massard@gustaveroussy.fr
- Contact Person Name
- Christophe Massard
- Contact Person Email
- christophe.massard@gustaveroussy.fr
Belgium
- Earliest CTIS Part Ii Submission Date
- 25-06-2025
- Latest Decision Or Authorization Date
- 15-07-2025
- Processing Time Days
- 20
- Number Of Sites
- 4
- Number Of Participants
- 32
Sites
- Site Name
- UZ Leuven
- Department Name
- Department of general medical oncology
- Principal Investigator Name
- Patrick Schöffski
- Principal Investigator Email
- patrick.schoffski@uzleuven.be
- Contact Person Name
- Patrick Schöffski
- Contact Person Email
- patrick.schoffski@uzleuven.be
- Site Name
- Universitair Ziekenhuis Gent
- Department Name
- Medical oncology
- Principal Investigator Name
- Sylvie Rottey
- Principal Investigator Email
- sylvie.rottey@ugent.be
- Contact Person Name
- Sylvie Rottey
- Contact Person Email
- sylvie.rottey@ugent.be
- Site Name
- Institut Jules Bordet
- Department Name
- Oncology
- Principal Investigator Name
- Nuria Kotecki
- Principal Investigator Email
- nuria.kotecki@hubruxelles.be
- Contact Person Name
- Nuria Kotecki
- Contact Person Email
- nuria.kotecki@hubruxelles.be
- Site Name
- Cliniques Universitaires Saint-Luc
- Department Name
- Medical Oncology / Institut Roi Albert II
- Principal Investigator Name
- Rachel Galot
- Principal Investigator Email
- rachel.galot@saintluc.uclouvain.be
- Contact Person Name
- Rachel Galot
- Contact Person Email
- rachel.galot@saintluc.uclouvain.be
Czechia
- Earliest CTIS Part Ii Submission Date
- 17-06-2025
- Latest Decision Or Authorization Date
- 15-07-2025
- Processing Time Days
- 28
- Number Of Sites
- 2
- Number Of Participants
- 17
Sites
- Site Name
- Masarykuv Onkologicky Ustav
- Department Name
- Clinic of Comprehensive Cancer Care
- Principal Investigator Name
- Radka Lordick Obermannová
- Principal Investigator Email
- radka.obermannova@mou.cz
- Contact Person Name
- Radka Lordick Obermannová
- Contact Person Email
- radka.obermannova@mou.cz
- Site Name
- University Hospital Olomouc
- Department Name
- Department of Oncology
- Principal Investigator Name
- Hana Študentová
- Principal Investigator Email
- hana.studentova@fnol.cz
- Contact Person Name
- Hana Študentová
- Contact Person Email
- hana.studentova@fnol.cz
Spain
- Earliest CTIS Part Ii Submission Date
- 02-07-2025
- Latest Decision Or Authorization Date
- 16-07-2025
- Processing Time Days
- 14
- Number Of Sites
- 3
- Number Of Participants
- 26
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Vall d’Hebron Institute of Oncology
- Principal Investigator Name
- Elena Garralda
- Principal Investigator Email
- egarralda@vhio.net
- Contact Person Name
- Elena Garralda
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Centro Integral Oncológico Clara Campall (CIOCC) Phase I trials unit
- Principal Investigator Name
- Emiliano Calvo
- Principal Investigator Email
- emiliano.calvo@startmadrid.com
- Contact Person Name
- Emiliano Calvo
- Contact Person Email
- emiliano.calvo@startmadrid.com
- Site Name
- Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De Compostela
- Department Name
- Oncology Department, Hospital Clínico Universitario Santiago de Compostela
- Principal Investigator Name
- Vanesa Varela
- Principal Investigator Email
- vanesa.varela.pose@sergas.es
- Contact Person Name
- Vanesa Varela
- Contact Person Email
- vanesa.varela.pose@sergas.es
Netherlands
- Earliest CTIS Part Ii Submission Date
- 18-06-2025
- Latest Decision Or Authorization Date
- 21-07-2025
- Processing Time Days
- 33
- Number Of Sites
- 2
- Number Of Participants
- 9
Sites
- Site Name
- Netherlands Cancer Institute
- Department Name
- Department of medical oncology
- Principal Investigator Name
- Tim Schutte
- Principal Investigator Email
- t.schutte@nki.nl
- Contact Person Name
- Tim Schutte
- Contact Person Email
- t.schutte@nki.nl
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Department of Medical Oncology
- Principal Investigator Name
- Daan Knapen
- Principal Investigator Email
- d.g.knapen@umcg.nl
- Contact Person Name
- Daan Knapen
- Contact Person Email
- d.g.knapen@umcg.nl
Sponsor
Primary sponsor
- Full Name
- Epics Therapeutics
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- EP102
Related trials
Other published trials that may interest you.